JP2012176956A5 - - Google Patents

Download PDF

Info

Publication number
JP2012176956A5
JP2012176956A5 JP2012092614A JP2012092614A JP2012176956A5 JP 2012176956 A5 JP2012176956 A5 JP 2012176956A5 JP 2012092614 A JP2012092614 A JP 2012092614A JP 2012092614 A JP2012092614 A JP 2012092614A JP 2012176956 A5 JP2012176956 A5 JP 2012176956A5
Authority
JP
Japan
Prior art keywords
group
substituted
hydroxy
composition according
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012092614A
Other languages
English (en)
Japanese (ja)
Other versions
JP5969255B2 (ja
JP2012176956A (ja
Filing date
Publication date
Priority claimed from US10/754,547 external-priority patent/US20050154046A1/en
Application filed filed Critical
Publication of JP2012176956A publication Critical patent/JP2012176956A/ja
Publication of JP2012176956A5 publication Critical patent/JP2012176956A5/ja
Application granted granted Critical
Publication of JP5969255B2 publication Critical patent/JP5969255B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012092614A 2004-01-12 2012-04-16 炎症関連疾患の治療法 Expired - Fee Related JP5969255B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/754,547 US20050154046A1 (en) 2004-01-12 2004-01-12 Methods of treating an inflammatory-related disease
US10/754,547 2004-01-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006549356A Division JP5383977B2 (ja) 2004-01-12 2005-01-06 炎症関連疾患の治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014240778A Division JP2015071626A (ja) 2004-01-12 2014-11-28 炎症関連疾患の治療法

Publications (3)

Publication Number Publication Date
JP2012176956A JP2012176956A (ja) 2012-09-13
JP2012176956A5 true JP2012176956A5 (enExample) 2013-11-14
JP5969255B2 JP5969255B2 (ja) 2016-08-17

Family

ID=34739408

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006549356A Expired - Fee Related JP5383977B2 (ja) 2004-01-12 2005-01-06 炎症関連疾患の治療法
JP2012092614A Expired - Fee Related JP5969255B2 (ja) 2004-01-12 2012-04-16 炎症関連疾患の治療法
JP2014240778A Pending JP2015071626A (ja) 2004-01-12 2014-11-28 炎症関連疾患の治療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006549356A Expired - Fee Related JP5383977B2 (ja) 2004-01-12 2005-01-06 炎症関連疾患の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014240778A Pending JP2015071626A (ja) 2004-01-12 2014-11-28 炎症関連疾患の治療法

Country Status (15)

Country Link
US (2) US20050154046A1 (enExample)
EP (3) EP3020400A1 (enExample)
JP (3) JP5383977B2 (enExample)
CA (2) CA2547963C (enExample)
CY (1) CY1115289T1 (enExample)
DK (1) DK1706112T3 (enExample)
ES (2) ES2559183T3 (enExample)
HK (1) HK1220612A1 (enExample)
HR (1) HRP20140536T1 (enExample)
ME (1) ME01878B (enExample)
PL (1) PL1706112T3 (enExample)
PT (1) PT1706112E (enExample)
RS (1) RS53372B (enExample)
SI (1) SI1706112T1 (enExample)
WO (1) WO2005069933A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EA200900786A1 (ru) * 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида
CN101296706B (zh) 2005-09-01 2011-11-30 先灵公司 Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
WO2007033208A2 (en) * 2005-09-12 2007-03-22 University Of Maryland Biotechnology Institute Off. Of Research Admin/Tech. Dev. Use of indirubin and its derivatives in the treatments of hiv infection and heart failure
US20090325931A1 (en) * 2006-07-28 2009-12-31 University Court Of The University Of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
JP5622720B2 (ja) * 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
EP2193790A1 (en) * 2008-12-04 2010-06-09 Klinikum der Universität Regensburg IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
WO2011127175A1 (en) * 2010-04-06 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cd130 (gp130) expression
CN102614122B (zh) * 2011-01-28 2013-10-16 上海现代药物制剂工程研究中心有限公司 酮咯酸氨丁三醇鼻腔喷雾剂及其制备方法
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
JP6382187B2 (ja) 2012-06-21 2018-08-29 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
MX2015013021A (es) 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3065861A2 (en) 2013-11-06 2016-09-14 Watt Fuel Cell Corp. Chemical reactor with manifold for management of a flow of gaseous reaction medium thereto
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3741368B1 (en) 2018-01-18 2024-03-06 Keio University Capsule for use in treating ulcerative colitis
CN118515598A (zh) * 2018-12-07 2024-08-20 斯塔蒂亚生物制药有限公司 甲异靛的多晶型和甲异靛的改进制剂
JP7085073B2 (ja) * 2019-04-17 2022-06-15 アゾーラ セラピューティクス，インコーポレイテッド 炎症性皮膚疾患を処置するための局所組成物及び方法
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2021207489A1 (en) * 2020-04-08 2021-10-14 Rtu Pharmaceuticals, Llc Methods and pharmaceutical compositions to treat pulmonary inflammation in infected patients
US11345818B1 (en) 2020-12-29 2022-05-31 Industrial Technology Research Institute Dye for fiber and dyeing method
JPWO2023286694A1 (enExample) * 2021-07-13 2023-01-19
AU2022360542A1 (en) 2021-10-08 2024-04-18 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995030A (en) * 1971-01-06 1976-11-30 Robert Daniels & Company, Inc. Composition and method for treating arthritis
US4118484A (en) * 1976-03-29 1978-10-03 The Upjohn Company Method of treating rheumatoid arthritis
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4049824A (en) * 1976-05-03 1977-09-20 Harry Weldon Diehl Cetyl myristoleate
US4176179A (en) * 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
US4468398A (en) * 1978-08-11 1984-08-28 Johnson Lewis A Method for treatment of rheumatoid arthritis
US4322405A (en) * 1981-04-06 1982-03-30 Laboratoires Om Societe Anonyme Method for treating rheumatoid arthritis
US4375468A (en) * 1981-07-13 1983-03-01 Verex Laboratories, Inc. Constant order release aspirin composition and method of treating arthritis
FR2516368B1 (fr) 1981-11-13 1985-06-21 Pigeon Daniel Meuble assemblable et demontable manuellement
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4500533A (en) * 1983-06-22 1985-02-19 Eli Lilly And Company 2,4,5-Triaryl pyrimidines and a method of treating pain, fever, thrombosis, inflammation and arthritis
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
JPS617254A (ja) 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
MX168552B (es) * 1985-02-19 1993-05-31 Jensen Charles A Procedimiento para la preparacion de polvo mineral inorganico
US5061475A (en) * 1985-06-07 1991-10-29 Cadema Medical Products, Inc. Composition and method of treatment of arthritis and related diseases with holmium-166 radionuclides
US5026538A (en) * 1985-06-07 1991-06-25 Cadema Medical Products, Inc. Method of treating arthritis, including rheumatoid arthritis, with 166 Holmium radionuclide
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US4732752A (en) * 1986-10-23 1988-03-22 Peter Stephan Center, Ltd. Polyvalent equine immune serum composition and method for treating rheumatoid arthritis
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US5061724A (en) * 1989-07-18 1991-10-29 Sheldon Gertner Method for treating arthritically inflamed body joints, particularly joints having gouty arthritis
US5149688A (en) * 1990-04-24 1992-09-22 Cetus Corporation Methods, compounds, and compositions for immunosuppression
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
CA2087147A1 (en) * 1992-01-17 1993-07-18 William Drell Method for administration of azauridine for the treatment of rheumatoid arthritis
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
JP3565442B2 (ja) * 1993-04-22 2004-09-15 新日本石油化学株式会社 哺乳類の関節炎の診断剤および／または治療剤
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US6033672A (en) * 1996-03-15 2000-03-07 University Of Southern California Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens
US5770357A (en) * 1996-03-15 1998-06-23 Univ Southern California Method of diagnosing caprine arthritis-encephalitis virus infection
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis
ATE429241T1 (de) * 1996-11-27 2009-05-15 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid- erzeugung
US5952367A (en) * 1997-04-25 1999-09-14 Pak; Kyoungsik Method of treating pain cause by bursitis tendinitis arthritis
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5849323A (en) * 1997-06-12 1998-12-15 A. Glenn Braswell Collagen mimetic and method of treating rheumatoid arthritis using same
US5849336A (en) * 1997-07-02 1998-12-15 Abbott Laboratories Method using sturgeon notochord for alleviating the symptoms of arthritis
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
US6040306A (en) * 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
JP2002508324A (ja) * 1997-12-13 2002-03-19 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼ阻害剤としてのピラゾロ［３，４−ｂ］ピリジンの使用
KR100261114B1 (ko) * 1998-01-24 2000-07-01 박종헌 히스톤을 함유하는 류마티스 관절염 치료제 조성물
DK1079826T3 (da) 1998-05-29 2003-06-23 Centre Nat Rech Scient Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser
ES2237919T4 (es) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
US6524625B2 (en) * 1998-06-30 2003-02-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuto Physiologically active extract obtained from indigo plant polygonum tinctorium
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
MXPA01007851A (es) * 1999-02-01 2003-06-04 Cv Therapeutics Inc Inhibidores purina de cinasa 2 e 1kb-alfa dependientes del ciclin.
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
BR0009771A (pt) 1999-04-12 2002-01-08 Gerhard Eisenbrand Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
AU4117800A (en) 1999-04-12 2000-11-14 Gerhard Eisenbrand Indigoid bisindole derivatives
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
AU772841B2 (en) * 1999-09-14 2004-05-06 Merck Frosst Canada Ltd. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
EP1110549A1 (en) * 1999-12-23 2001-06-27 Warner-Lambert Company Use of trimebutine for treating pain
EP1280789A1 (en) * 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
AU2001290316A1 (en) * 2000-10-02 2002-04-15 Mochida Pharmaceutical Co., Ltd. Gata-3 expression inhibitor and method of screening the same
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
EP1458734B1 (en) * 2001-12-13 2010-10-13 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
JP4291696B2 (ja) * 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US20050090426A1 (en) * 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation

Similar Documents

Publication Publication Date Title
JP2012176956A5 (enExample)
JP2007522114A5 (enExample)
AU2021251689B2 (en) Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
AU2019231725B2 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AU2015303835B2 (en) Lymph directing prodrugs
JP2021152074A (ja) ステロイドの抗痙攣活性
EP3068776B1 (en) Inhibitors of influenza viruses replication
JP6530056B2 (ja) 骨選択的骨形成オキシステロールビスホスホネート類似体
CN104688737B (zh) 用于治疗cmt及相关病症的新组合物
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CA3077739A1 (en) Lymphatic system-directing lipid prodrugs
JP2013541519A (ja) 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
TWI845826B (zh) 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
CN110248951A (zh) 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
CN105985395A (zh) 一种奥贝胆酸化合物及含有该化合物的药物组合物
US20240165143A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2016516773A5 (enExample)
BR112014018393A8 (pt) Composição farmacêutica adequada para liberação ocular de um esteroide e uso da mesma para a fabricação de um medicamento para tratar uma doença oftálmica
Zhang et al. Effects of ablation and activation of Nrf2 on bile acid homeostasis in male mice
CN111971049A (zh) 促进免疫应答
Turner et al. TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs
JP7786743B2 (ja) ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
JP2019014684A5 (enExample)
CN102872029B (zh) Gypensapogenin B在制备促进小肠蠕动药物中的应用
Iyer et al. Sublingual Delivery of SB 9000—An Anti-HBV Dinucleoside Phosphorothioate Analog